{"id":"4e8400ccc6f6","type":"article","url":"https://hartvaat.nl/2026/09/01/tirzepatide-zorgt-voor-sterk-gewichtsverlies-bij-vrouwen-met-pcos-en-obesitas/","title":"Tirzepatide zorgt voor sterk gewichtsverlies bij vrouwen met PCOS en obesitas","title_en":"Weight loss outcomes with tirzepatide in women with and without self-reported polycystic ovary syndrome.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","huisarts","internist"],"tags":[],"journal":"Journal of the Endocrine Society","doi":"10.1210/jendso/bvag177","source_url":"https://doi.org/10.1210/jendso/bvag177","authors":["Ashley Kieran Clift","Dan Reisel","Hans Johnson","Naveed Sattar","David R Huang"],"significance":5,"published":"2026-08-31","source_date":"2026-09-01","image":"","kennis":[],"congress":"","summary_en":"A retrospective open-cohort study of over 54,000 women with obesity in the UK evaluated tirzepatide-induced weight loss, with a specific focus on those with self-reported polycystic ovary syndrome (PCOS). At 10 months, mean weight reduction was 19.4% in the PCOS subgroup, comparable to the 18.7% observed in women without PCOS, with 57.7% of PCOS patients achieving ≥20% total body weight loss. Digital engagement further amplified weight loss outcomes. These findings reinforce tirzepatide as a highly effective therapeutic option for weight management in women with PCOS, offering valuable insights for primary care physicians and internists managing cardiometabolic risk.","created":"2026-08-25T01:00:35Z","updated":"2026-08-25T01:00:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Een retrospectieve cohortstudie onder meer dan 54.000 vrouwen met obesitas in het VK onderzocht het effect van tirzepatide op gewichtsverlies, specifiek bij vrouwen met zelfgerapporteerd PCOS. Na tien maanden daalde het gemiddelde lichaamsgewicht met 19,4% bij vrouwen met PCOS, wat niet significant verschilde van de groep zonder PCOS (18,7%). Ruim 57% van de vrouwen met PCOS behaalde een gewichtsverlies van ≥20%. Deze bevindingen bevestigen dat tirzepatide een effectieve optie is voor gewichtsmanagement bij vrouwen met PCOS, wat relevant is voor de primaire zorg en internisten gezien de sterke link tussen obesitas, PCOS en cardiovasculair risicomanagement.","abstract_original":"CONTEXT: Weight management is key to managing polycystic ovary syndrome (PCOS) and overweight/obesity but is challenging for many. Evidence regarding tirzepatide's efficacy in women with polycystic ovary syndrome is limited. OBJECTIVES: To quantify the effectiveness of tirzepatide for weight loss in women with (self-reported) polycystic ovary syndrome and overweight/obesity compared with women not living with PCOS and to explore associations between engagement with nonpharmacological digital adjuncts and weight loss. METHODS: Retrospective open-cohort study in a digital weight management service in the United Kingdom. All women (aged 18+ years) with overweight/obesity prescribed tirzepatide for weight management between February 2024 and January 2025 were included. Percentage weight change from baseline was calculated in women reaching specific follow-up time points, stratified by PCOS status. Kaplan-Meier methods estimated cumulative probabilities of attaining total body weight loss thresholds. RESULTS: The cohort comprised 54 114 women of whom 4241 (7.84%) women had PCOS. At 10 months, the mean weight change in women with PCOS (n = 40) was -19.40% (95% confidence interval [CI], -22.38% to -16.42%); this was not significantly different from women without PCOS (n = 397; mean weight change, -18.74%; 95% CI, -19.67% to -17.81%). A total of 57.66% of women with PCOS lost ≥20% total body weight (95% CI, 47.44% to 68.29%) by 10 months. In women living with PCOS, digitally engaged women lost 3.42% more weight in absolute terms (95% CI, 1.71% to 5.12%; P < .001) by 10 months. CONCLUSION: Tirzepatide may offer a highly effective therapeutic option for women with PCOS and overweight/obesity in whom weight loss is a key goal but a persistent challenge."}